Macrocyclic Apratoxin Analogues Reduce In Vivo Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Apratoxins, derived from marine cyanobacteria, exhibit potent cytotoxic activity but face challenges such as in vivo toxicity and sub-optimal tolerability, limiting their therapeutic potential for cancer and other diseases.
Innovation Solution
Development of macrocyclic compounds with novel chemical scaffolds and synthetic analogues that modulate cellular activity, specifically targeting cotranslational translocation and receptor downregulation, to enhance antiproliferative activity and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If apratoxins are used for their potent cytotoxic activity, then antiproliferative effect is improved, but in vivo toxicity increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of apratoxins through systematic variations in ring size, substitution patterns, and stereochemistry. These structural parameter changes result in analogues with improved therapeutic indices, maintaining nanomolar antiproliferative activity while reducing in vivo toxicity and sub-optimal tolerability associated with natural apratoxins.
Solution Approach 2:
The patent employs local quality by making specific localized modifications to different regions of the apratoxin molecular scaffold. By varying substituents at specific positions and modifying particular ring systems while maintaining the core macrocyclic structure, the invention achieves selective optimization of biological activity and toxicity profile.
2Reliability
If apratoxins are used for cancer treatment, then therapeutic efficacy is improved, but tolerability deteriorates
Solution Approach 1:
The patent resolves this contradiction through parameter changes in the chemical structure of apratoxin analogues. By systematically varying molecular parameters such as ring size, functional group substitution, and stereochemical configuration, the invention produces compounds that maintain high therapeutic efficacy with improved tolerability profiles for cancer treatment.
Solution Approach 2:
The patent creates composite molecular structures by combining the core apratoxin scaffold with various modified side chains and functional groups. These composite analogues integrate the beneficial cytotoxic properties of natural apratoxins while incorporating modifications that reduce adverse effects and improve overall tolerability.
Data Source
AI summary
The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.